BACKGROUND: The goal of this study was to evaluate accelerated radiotherapy with and without temozolomide (TMZ) for glioblastoma multiforme (GBM). METHODS: This retrospective analysis evaluated 86 patients with histologically proven GBM who were treated with accelerated radiotherapy of 1.8 Gy twice daily to a total dose of 54 Gy within 3 weeks. Median age was 62 years and median Karnofsky index was 90. A total of 41 patients received radiotherapy only from 2002-2005 and 45 patients were treated with TMZ concomitantly and after radiotherapy from 2005-2007. RESULTS: Median overall survival (OS) was 12.5 months and 2-year OS was 15.4%. Patient characteristics were well balanced between the two groups except for better performance status (p = 0.05) and higher frequency of retreatment for the first recurrence (p = 0.02) in the TMZ group. Age at diagnosis (HR 2.83) and treatment with TMZ (HR 0.60) were correlated with OS in the multivariate analysis: treatment with and without TMZ resulted in median OS of 16 months and 11.3 months, respectively. Hematological toxicity grade > II was observed in 2/45 patients and 5/37 patients during simultaneous radiochemotherapy and adjuvant TMZ. CONCLUSION: TMZ added to accelerated radiotherapy for GBM resulted in prolonged overall survival with low rates of severe hematological toxicity.
BACKGROUND: The goal of this study was to evaluate accelerated radiotherapy with and without temozolomide (TMZ) for glioblastoma multiforme (GBM). METHODS: This retrospective analysis evaluated 86 patients with histologically proven GBM who were treated with accelerated radiotherapy of 1.8 Gy twice daily to a total dose of 54 Gy within 3 weeks. Median age was 62 years and median Karnofsky index was 90. A total of 41 patients received radiotherapy only from 2002-2005 and 45 patients were treated with TMZ concomitantly and after radiotherapy from 2005-2007. RESULTS: Median overall survival (OS) was 12.5 months and 2-year OS was 15.4%. Patient characteristics were well balanced between the two groups except for better performance status (p = 0.05) and higher frequency of retreatment for the first recurrence (p = 0.02) in the TMZ group. Age at diagnosis (HR 2.83) and treatment with TMZ (HR 0.60) were correlated with OS in the multivariate analysis: treatment with and without TMZ resulted in median OS of 16 months and 11.3 months, respectively. Hematological toxicity grade > II was observed in 2/45 patients and 5/37 patients during simultaneous radiochemotherapy and adjuvant TMZ. CONCLUSION:TMZ added to accelerated radiotherapy for GBM resulted in prolonged overall survival with low rates of severe hematological toxicity.
Authors: W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth Journal: J Clin Oncol Date: 2004-03-29 Impact factor: 44.544
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Philip H Gutin; Fabio M Iwamoto; Kathryn Beal; Nimish A Mohile; Sasan Karimi; Bob L Hou; Stella Lymberis; Yoshiya Yamada; Jenghwa Chang; Lauren E Abrey Journal: Int J Radiat Oncol Biol Phys Date: 2009-01-23 Impact factor: 7.038
Authors: Dirk Vordermark; Oliver Kölbl; Klemens Ruprecht; Giles H Vince; Klaus Bratengeier; Michael Flentje Journal: BMC Cancer Date: 2005-05-30 Impact factor: 4.430
Authors: L Fariselli; V Pinzi; I Milanesi; A Silvani; M Marchetti; M Farinotti; A Salmaggi Journal: Strahlenther Onkol Date: 2013-04-28 Impact factor: 3.621
Authors: M D Piroth; M Pinkawa; R Holy; J Klotz; S Schaar; G Stoffels; N Galldiks; H H Coenen; H J Kaiser; K J Langen; M J Eble Journal: Strahlenther Onkol Date: 2012-02-22 Impact factor: 3.621
Authors: Julia Alejandra Pezuk; María Sol Brassesco; Andressa Gois Morales; Jaqueline Carvalho de Oliveira; Harley Francisco de Oliveira; Carlos Alberto Scrideli; Luiz Gonzaga Tone Journal: Cancer Biother Radiopharm Date: 2013-05-28 Impact factor: 3.099
Authors: M Balducci; B Diletto; S Chiesa; G R D'Agostino; M A Gambacorta; M Ferro; C Colosimo; G Maira; C Anile; V Valentini Journal: Strahlenther Onkol Date: 2014-01-17 Impact factor: 3.621
Authors: Piernicola Pedicini; Alba Fiorentino; Vittorio Simeon; Paolo Tini; Costanza Chiumento; Luigi Pirtoli; Marco Salvatore; Giovanni Storto Journal: Strahlenther Onkol Date: 2014-04-04 Impact factor: 3.621
Authors: Leilane Sales; Julia Alejandra Pezuk; Kleiton Silva Borges; María Sol Brassesco; Carlos Alberto Scrideli; Luiz Gonzaga Tone; Marcelo Henrique dos Santos; Marisa Ionta; Jaqueline Carvalho de Oliveira Journal: BMC Complement Altern Med Date: 2015-10-30 Impact factor: 3.659
Authors: Justyna Moskwa; Maria H Borawska; Renata Markiewicz-Zukowska; Anna Puscion-Jakubik; Sylwia K Naliwajko; Katarzyna Socha; Jolanta Soroczynska Journal: PLoS One Date: 2014-03-04 Impact factor: 3.240